Skip to main content
F
Formulate
Jobs
Companies
Drugs
Advisor
NEW
Insider Intel
Salary
Pricing
Toggle theme
Toggle theme
Menu
argenx Jobs | Formulate
Jobs
argenx
argenx Jobs
Belgium - Zwijnaarde
Biotechnology
argenx is a life sciences company focused on Antibody therapies.
124
open positions at argenx
View Full Profile
Filters:
Immunology ×
Director, Biostatistics and Modeling
argenx
Posted 2mo ago
Gent, Belgium
Full-time
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Data Science
Immunology
Executive
H-1B · 1 FY23
Project Toxicologist
argenx
Posted 2mo ago
Gent, Belgium
Full-time
Global DT Lead Development
argenx
Posted 2mo ago
Remote
Full-time
Business Leader, Southwest (Southwest)
argenx
Posted 2mo ago
United States - Field
$204K - $281K
Full-time
Market Head (Regional General Manager) - Florida & Puerto Rico
argenx
Posted 2mo ago
United States - Field
$236K - $325K
Full-time
Business Leader, Rocky Plains (Rocky Mountains)
argenx
Posted 2mo ago
United States - Field
$204K - $281K
Full-time
Business Leader, Mid-Atlantic (Mid-Atlantic)
argenx
Posted 2mo ago
United States - Field
$204K - $281K
Full-time
Business Leader, Southeast (North Carolina & Virginia)
argenx
Posted 2mo ago
United States - Field
$204K - $281K
Full-time
Business Leader, Great Lakes (Michigan)
argenx
Posted 2mo ago
United States - Field
$204K - $281K
Full-time
Business Leader, Los Angeles
argenx
Posted 2mo ago
United States - Field
$204K - $281K
Full-time
Market Head (Regional General Manager) - South Central
argenx
Posted 2mo ago
United States - Field
$236K - $325K
Full-time
Market Head (Regional General Manager) - Midwest
argenx
Posted 2mo ago
United States - Field
$236K - $325K
Full-time
Trial Operations Excellence & Innovation Lead
argenx
Posted 2mo ago
Remote
Full-time
Program Director, Governance Forums
argenx
Posted 3mo ago
Remote
$212K - $292K
Full-time
Clinical Operations Development Lead
argenx
Posted 3mo ago
Remote
$212K - $292K
Full-time
DT AI Platform Lead
argenx
Posted 3mo ago
Gent, Belgium
Full-time
Toxicologist late stage clinical development and established Assets
argenx
Posted 4mo ago
Gent, Belgium
Full-time
Digital Technology Business Lead - Research
argenx
Posted 5mo ago
Gent, Belgium
Full-time
Digital Technology Product Owner, US Market Access
argenx
Posted 5mo ago
Boston, MA, USA
$156K - $215K
Full-time
Digital Technology Product Owner, US HCP Experience
argenx
Posted 5mo ago
Boston, MA, USA
$184K - $253K
Full-time
Previous
1
2
3
Company Overview
Active Jobs
171
Pipeline Programs
88
Drug Products
2
Clinical Trials
91
View Full Company Profile
Therapeutic Areas
Neurology
Immunology
Oncology
Links
Company Website
Careers Page
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Remote
Immunology
Senior
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
EXECUTIVE
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
EXECUTIVE
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
EXECUTIVE
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Remote
Immunology
Senior
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Remote
Immunology
Executive
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Remote
Clinical Operations
Immunology
Senior
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
Senior
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Clinical Development
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Research & Development
Immunology
Senior
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Commercial
Immunology
MID
H-1B · 1 FY23
Related drug:
VYVGART
Condition in scope:
Neonatal Presentation (First 28 Days of Life)
Immunology
MID
H-1B · 1 FY23
4
5
6
7
Next
Hematology
Rare Diseases